Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range ...
ENTR-601-44 is the lead product candidate in Entrada Therapeutics' pipeline. Utilizing the company's proprietary Endosomal Escape Vehicle (EEV) platform, this therapeutic is engineered to improve the intracellular delivery of oligonucleotides. It is currently under preclinical assessment to treat Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) by effectively crossing cell membranes to reach the intended site of action.
Price Range: N/A (Clinical/Preclinical stage)
Pain Points: Solves the 'endosomal trap' problem where traditional therapeutics fail to reach the cytoplasm in sufficient quantities due to degradation in endosomes.
Solutions: Provides efficient intracellular delivery of genetic medicines, potentially restoring protein expression or correcting genetic defects in patients with neuromuscular diseases.
Target Users: Patients diagnosed with Duchenne muscular dystrophy or myotonic dystrophy type 1, and healthcare providers specializing in rare genetic neuromuscular diseases.
Supply Chain
Contract manufacturing organizations (CMOs) for drug substance productionSpecialized chemical and biochemical raw material suppliersClinical research organizations (CROs) for preclinical and clinical trial management
EEV-PMO-CAG is a therapeutic candidate designed to address the underlying cause of myotonic dystrophy type 1. By leveraging the EEV platform to facilitate the delivery of PMOs into the cell, this product aims to modulate RNA processes to mitigate the symptoms of DM1.
Price Range: N/A (Preclinical stage)
Pain Points: Low cellular uptake and poor intracellular bioavailability of traditional PMOs in skeletal and cardiac muscle tissues.
Solutions: Enhances the delivery and potency of PMO treatments, allowing for a more effective reduction of toxic RNA aggregates associated with DM1.
Target Users: Patients living with myotonic dystrophy type 1 and medical institutions focusing on genetic muscle disorders.
Supply Chain
Contract manufacturing organizations (CMOs) for drug substance productionSpecialized biochemical synthesis laboratoriesClinical research organizations (CROs) for research and development support
Vertex Pharmaceuticals IncorporatedNASDAQ:VRTXPatients with Duchenne Muscular Dystrophy (DMD)Patients with Usher Syndrome Type 2A (USH2A) / Inherited Retinal DiseasesPatients with Myotonic Dystrophy Type 1 (DM1)
